Support for venture capital firms, angel investors and family offices evaluating companies in genomics, biotechnology, synthetic biology, precision medicine and AI-driven life science.
The owner of The Genomic Power Shift is a serial entrepreneur with experience in technical due diligence of biotech companies. This service helps investors understand the science, assess the claims, identify risks and evaluate whether a company’s technology is plausible, differentiated and commercially meaningful.
Support can include
- Technical due diligence of biotech and genomics companies
- Assessment of scientific claims and technical feasibility
- Review of platform technologies, pipelines and defensibility
- Evaluation of AI-biology and computational biology claims
- Founder, product and market-risk assessment
- Strategic questions for investment committees
- Independent second opinions before investment decisions
Interested in working together?
For speaking, media, investment, strategy or advisory enquiries, get in touch.